Abstract: A chimeric antigen receptor, includes an extracellular domain, a transmembrane domain, and an intracellular domain, which are connected in sequence, where the extracellular domain includes an antigen recognition region and a hinge region, and one end of the intracellular domain which is connected to the transmembrane domain is connected to a CD3? intracellular region. The chimeric antigen receptor can further improve the treatment effect of B-cell leukemia lymphoma, and reduce inflammatory cytokines generated from macrophage mononuclear cell activation by down-regulating cytokines, so that cytokine storm can be prevented in an early stage, and the risk of neurotoxicity can be reduced. The treatment effect of mesothelin high-expression solid tumors is further improved in mesothelin-positive tumor treatment, and the prevention of cytokine storm and the reduced risk of neurotoxicity can be realized at an early stage.

Abstract: A chimeric antigen receptor containing a CD3? intracellular region with a Y/F mutation, includes an extracellular domain, a transmembrane domain, and an intracellular domain which are connected in sequence, where one end of the intracellular domain, which is connected to the transmembrane domain, is connected to the CD3? intracellular region with the Y/F mutation, and the CD3? intracellular region with the Y/F mutation refers to a Y/F mutant CD3? intracellular region in which both tyrosines are mutated to phenylalanines in the ITAM of the CD3? intracellular region. T cells modified with the chimeric antigen receptor have improved viability, decreased apoptosis level, and increased proliferation ability, and down-regulate the expression levels of cytokines IFN-? and TNF-?.